Gelesis Holdings, Inc. (GLSHQ)

OTCMKTS: GLSHQ · Delayed Price · USD
0.0198
0.00 (0.00%)
Mar 20, 2024, 10:04 AM EDT - Market closed
Market Cap 1.45M
Revenue (ttm) 12.14M
Net Income (ttm) -51.67M
Shares Out 73.34M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,018
Open 0.0198
Previous Close 0.0198
Day's Range 0.0198 - 0.0198
52-Week Range 0.0003 - 0.2020
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About GLSHQ

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporate... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 93
Stock Exchange OTCMKTS
Ticker Symbol GLSHQ
Full Company Profile

Financial Performance

In 2022, GLSHQ's revenue was $25.77 million, an increase of 130.37% compared to the previous year's $11.19 million. Losses were -$95.06 million, -49.40% less than in 2021.

Financial Statements

News

Cell Reports Medicine Publication Demonstrates How Gelesis' Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--A new paper published today in Cell Reports Medicine suggests that weight loss resulting from Gelesis' superabsorbent hydrogel treatment is not only a resul...

5 months ago - Business Wire

Gelesis' Oral Treatment for Weight Management Showed Real-World Effectiveness in New Data Presented at the American Diabetes Association's Annual Conference

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis, the maker of Plenity for weight management, presented a late-breaking poster presentation at the American Diabetes Association's (ADA) 2023 annual ...

9 months ago - Business Wire

NYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting Proceedings

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of G...

1 year ago - Business Wire

Gelesis Reports Fourth Quarter and Full Year 2022 Results

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the year e...

1 year ago - Business Wire

Gelesis to Participate in the 25th Annual ICR Conference

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on M...

1 year ago - Business Wire

NYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting Proceedings

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Gel...

1 year ago - Business Wire

Gelesis Reports Upcoming Participation in Wolfe Research's Annual Consumer Growth Conference

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that its Chief Operating & Commercial Officer, D...

1 year ago - Business Wire

Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that on November 16, 2022, the Company received a notification letter (the “Notice”) from the New ...

1 year ago - Business Wire

Gelesis Reports Third Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. ...

1 year ago - Business Wire

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for...

1 year ago - Business Wire

Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) today noted that the Company received a notification letter from the New York Stock Exchange (the “NYSE”) advisi...

1 year ago - Business Wire

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

1 year ago - Business Wire

Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis' Oral Hydrogel Treatment GS200 at Obesity Week

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced Dr. Frank Greenway will give an oral presentation at...

1 year ago - Business Wire

Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Offi...

1 year ago - Business Wire

Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress o...

1 year ago - Business Wire

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat...

1 year ago - Business Wire

Gelesis Reports Second Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. “We are seeing both consumers and clinicians ...

1 year ago - Business Wire

Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022

BOSTON--(BUSINESS WIRE)--Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”), the maker of Plenity® for weight management, today announced that the Company will report financial results for...

1 year ago - Business Wire

Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million

BOSTON--(BUSINESS WIRE)--Gelesis announced today that Ro, a leading and rapidly growing U.S. direct-to-patient healthcare company, has placed a $15 million pre-paid order for the company's commercial ...

1 year ago - Business Wire

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new findings about the role of language in obesity and diabetes scientific literature at the America...

1 year ago - Business Wire

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis' Proprietary Hydrogel

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new preclinical data showing weight loss and additional metabolic benefits in mice receiving a micro...

1 year ago - Business Wire

Gelesis to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer,...

2 years ago - Business Wire

Gelesis Reports First Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the first quarter of 2022. “We saw all-time highs of people seeking and s...

2 years ago - Business Wire

Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on...

2 years ago - Business Wire

Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), a consumer-focused biotherapeutics company and the maker of Plenity®, today presented results from the LIGHT-UP clinical trial for adults with overweight ...

2 years ago - Business Wire